Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspire IVF PCLBKK:IVF -1.30%18 EV-to-EBITDA is 4.67 as of Aug. 28, 2026, which is 151% above its 10-year median of 1.86. GuruFocus rates BKK:IVF with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 517 Healthcare Providers & Services companies, Inspire IVF PCL ranks better than 86.27% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inspire IVF PCL's enterprise value is ฿-60.26 Mil.
Inspire IVF PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿-12.90 Mil. Therefore, Inspire IVF PCL's EV-to-EBITDA for today is 4.67.
The historical rank and industry rank for Inspire IVF PCL's EV-to-EBITDA or its related term are showing as below:
BKK:IVF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.63 Med: 1.86 Max: 42.88
Current: 4.67
During the past 5 years, the highest EV-to-EBITDA of Inspire IVF PCL was 42.88. The lowest was -9.63. And the median was 1.86.
BKK:IVF's EV-to-EBITDA is ranked better than 86.27% of 517
companies
in the Healthcare Providers & Services industry
Industry Median: 10.49
vs BKK:IVF: 4.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inspire IVF PCL's PE Ratio (TTM) for today is calculated as:
Inspire IVF PCL's share price for today is ฿0.76.
Inspire IVF PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Inspire IVF PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Inspire IVF PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspire IVF PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Inspire IVF PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inspire IVF PCL's EV-to-EBITDA falls into.
Inspire IVF PCL's current Enterprise Value is ฿-60.26 Mil.
Inspire IVF PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-12.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspire IVF PCL (BKK:IVF) has a EV-to-EBITDA of 4.67 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspire IVF PCL. This is 151% above median its historical median of 1.86. According to the industry distribution chart, Inspire IVF PCL ranks #71 out of 517 companies in the Healthcare Providers & Services industry, placing it in the top 13.7%.
Is Inspire IVF PCL's EV-to-EBITDA too high?
Inspire IVF PCL's current EV-to-EBITDA of 4.67 is 151% above median its 10-year median of 1.86. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.49. Inspire IVF PCL's value of 4.67 is 55.5% below this industry median. Based on the distribution chart, Inspire IVF PCL ranks #71 out of 517 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Inspire IVF PCL has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Inspire IVF PCL's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Inspire IVF PCL ranks #71 out of 517 companies for EV-to-EBITDA. This places Inspire IVF PCL in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.49. Inspire IVF PCL's value of 4.67 is 55.5% below this benchmark. While the company's 10-year median is 1.86 vs. the industry median of 10.49, Inspire IVF PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.49, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspire IVF PCL's current EV-to-EBITDA of 4.67 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspire IVF PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire IVF PCL's current EV-to-EBITDA is 4.67, which is 151% above median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire IVF PCL stock overvalued right now?
Inspire IVF PCL (BKK:IVF) has a current EV-to-EBITDA of 4.67. The current EV-to-EBITDA is 4.67, which is 151% above median its 10-year median of 1.86 and 55.5% below the Healthcare Providers & Services industry median of 10.49. Inspire IVF PCL's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Inspire IVF PCL (BKK:IVF), the current EV-to-EBITDA is 4.67 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inspire IVF PCL operates a comprehensive fertility treatment center, offering services ranging from consultations to selecting the appropriate treatment for each couple. It is principally engaged in infertility treatment and counseling services treatment with anti-aging medicine and health restoration, hemodialysis, blood filtration, and plasma filtration. The company operates in a single geographic area, Thailand.
18GF Score
Get the complete analysis for BKK:IVF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IVF has been successfully added to your 
